• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Genmab A/S

    < Previous 1 2 3 4 Next >
    News headline image
    Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
    From Genmab A/S
    Via Business Wire
    Tickers GMAB INCY
    News headline image
    Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
    From Genmab A/S
    Via Business Wire
    Tickers ABBV GMAB
    News headline image
    Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Publishes 2025 Annual Report
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Financial Results for the First Half of 2026
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Major Shareholder Announcement
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Financial Results for the First Quarter of 2026
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    News headline image
    Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
    From Genmab A/S
    Via GlobeNewswire
    News headline image
    Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    From Genmab A/S
    Via Business Wire
    Tickers GMAB
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.